Automated Ultrasensitive Detection of Light Chain Restriction in Lymphoproliferat

描述(申请人提供)：免疫球蛋白(Ig)轻链限制(LCR)检测是鉴别诊断的重要分子诊断工具，包括淋巴组织增生、不典型淋巴组织增生、慢性炎症和B细胞肿瘤。流式细胞术(FCM)可以检测到LCR是细胞表面异常的kappa/lambda比值。然而，FCM需要新鲜的(未固定的)组织。有些B细胞淋巴瘤缺乏FCM检测到的表面Ig表达，有些则表现为非特异性抗体结合。通常只有福尔马林固定的石蜡包埋(FFPE)组织可用于病理评估。目前鉴定FFPE组织中LCR的方法包括免疫组织化学(IHC)和常规显色原位杂交(CISH)，它们分别检测kappa或lambda蛋白和mRNA。然而，在许多非霍奇金淋巴瘤(NHL)中，包括最常见的滤泡性淋巴瘤、弥漫性大B细胞淋巴瘤、小B淋巴细胞性淋巴瘤和MALT型结外边缘带淋巴瘤，IHC和传统CISH都缺乏足够的灵敏度来检测LCR。RNAScope是一种新型的RNA原位杂交技术，具有单分子检测灵敏度，与FFPE组织完全兼容，可进行发色或荧光检测。我们已经建立了一种手动明场kappa和lambda双链RNA ISH方法用于LCR，它已经证明了对所有NHL亚型的广泛适用性。在这个项目中，我们将开发一种具有数字病理解释的全自动双链RNAScope LCR检测方法，这将极大地促进这一新检测方法的临床应用。

DESCRIPTION (provided by applicant): Immunoglobulin (Ig) light chain restriction (LCR) detection is an important molecular diagnostic tool in the differential diagnosis that includes lymphoid hyperplasia, atypical lymphoid hyperplasia, chronic inflammation, and B cell neoplasms. LCR can be detected by flow cytometry (FCM) as an abnormal kappa:lambda ratio on the cell surface. However, FCM requires fresh (unfixed) tissue. Some B cell lymphomas lack surface Ig expression detectable by FCM, some demonstrate nonspecific antibody binding. Often only formalin-fixed paraffin-embedded (FFPE) tissue is available for pathologic evaluation. Current methods of LCR identification in FFPE tissue include immunohistochemistry (IHC) and conventional chromogenic in situ hybridization (CISH), which measure kappa or lambda protein and mRNA, respectively. However, both IHC and conventional CISH lack sufficient sensitivity to detect LCR in many non-Hodgkin lymphoma (NHL), including the most common NHL variants - follicular lymphoma, diffuse large B cell lymphoma, small B lymphocytic lymphoma, and extranodal marginal zone lymphoma of MALT type. RNAscope is a novel RNA in situ hybridization technology which has single-molecule detection sensitivity and is fully compatible with FFPE tissue using either chromogenic or fluorescent detection. We have developed a manual bright-field kappa and lambda duplex RNA ISH assay for LCR, which has demonstrated broad applicability to all NHL subtypes. In this project, we will develop a fully automated duplex RNAscope LCR assay with digital pathology interpretation, which should greatly facilitate clinical adoption of this novel assay.